Presentation is loading. Please wait.

Presentation is loading. Please wait.

POLG defects cause degeneration of enhancer‐active regions of CNS

Published byAnna-Leena Kähkönen Modified over 5 years ago

Similar presentations

Presentation on theme: "POLG defects cause degeneration of enhancer‐active regions of CNS"— Presentation transcript:

1 POLG defects cause degeneration of enhancer‐active regions of CNS
POLG defects cause degeneration of enhancer‐active regions of CNS Spinal cord (C8 level) of MIRAS patient, neurofilament staining. Dorsal columns, especially the gracile, show pallor (dashed line with star); motoneurons in the anterior horns are preserved (dashed line with black arrow). Scale bar 1 mm.Oculomotor complex of POLG patient with progressive ophthalmoplegia; midbrain level. Hematoxylin–eosin staining. The whole area shows spongiotic degeneration. Scale bar 50 μm. Joni Nikkanen et al. EMBO Mol Med. 2017;emmm © as stated in the article, figure or figure legend

Download ppt "POLG defects cause degeneration of enhancer‐active regions of CNS"

Similar presentations

Axonal loss in the pathology of MS: consequences for understanding the progressive phase of the disease  C Bjartmar, J.R Wujek, B.D Trapp  Journal of.

Axonal loss in the pathology of MS: consequences for understanding the progressive phase of the disease  C Bjartmar, J.R Wujek, B.D Trapp  Journal of.
Effects of inhibiting inflammatory cell recruitment on fracture healing Treatment with CCR2 antagonist, INCB3344, led to impaired fracture healing compared.

Effects of inhibiting inflammatory cell recruitment on fracture healing Treatment with CCR2 antagonist, INCB3344, led to impaired fracture healing compared.
Systemic inflammation activates the exosomal machinery in the choroid plexus Systemic inflammation activates the exosomal machinery in the choroid plexus.

Systemic inflammation activates the exosomal machinery in the choroid plexus Systemic inflammation activates the exosomal machinery in the choroid plexus.
Surface distribution of immunogold‐labelled PS I (A–C) and ATP synthase (D–F) complexes. Surface distribution of immunogold‐labelled PS I (A–C) and ATP.

Surface distribution of immunogold‐labelled PS I (A–C) and ATP synthase (D–F) complexes. Surface distribution of immunogold‐labelled PS I (A–C) and ATP.
Expression analyses of KLK7 mRNA in the brains of AD patients

Expression analyses of KLK7 mRNA in the brains of AD patients
PERK activator reduces behavioral deficits and neurodegeneration in vivo PERK activator reduces behavioral deficits and neurodegeneration in vivo A–CYoung.

PERK activator reduces behavioral deficits and neurodegeneration in vivo PERK activator reduces behavioral deficits and neurodegeneration in vivo A–CYoung.
The gene encoding TP53INP1 is expressed in pancreatic endocrine cells A, B(A, B) Immunocytofluorescent staining of TP53INP1 (red) and insulin (green) in.

The gene encoding TP53INP1 is expressed in pancreatic endocrine cells A, B(A, B) Immunocytofluorescent staining of TP53INP1 (red) and insulin (green) in.
PbA‐specific CD4 T‐cell responses are maximal at day 6 post‐pRBC infection PbA‐specific CD4 T‐cell responses are maximal at day 6 post‐pRBC infection Proportion.

PbA‐specific CD4 T‐cell responses are maximal at day 6 post‐pRBC infection PbA‐specific CD4 T‐cell responses are maximal at day 6 post‐pRBC infection Proportion.
Acetylcholine/muscarinic signaling maintains SOX2 and the acinar lineage in human SG Acetylcholine/muscarinic signaling maintains SOX2 and the acinar lineage.

Acetylcholine/muscarinic signaling maintains SOX2 and the acinar lineage in human SG Acetylcholine/muscarinic signaling maintains SOX2 and the acinar lineage.
TFE3 regulates glucose homeostasis

TFE3 regulates glucose homeostasis
AAV8‐hAAT‐FGF21 treatment improves liver fibrosis

AAV8‐hAAT‐FGF21 treatment improves liver fibrosis
Treatment with FGF21‐encoding vectors reverses hepatic steatosis and fibrosis Treatment with FGF21‐encoding vectors reverses hepatic steatosis and fibrosis.

Treatment with FGF21‐encoding vectors reverses hepatic steatosis and fibrosis Treatment with FGF21‐encoding vectors reverses hepatic steatosis and fibrosis.
CAR T cell dose and percentages of CAR‐positive cells within CAR T cell products CAR T cell dose and percentages of CAR‐positive cells within CAR T cell.

CAR T cell dose and percentages of CAR‐positive cells within CAR T cell products CAR T cell dose and percentages of CAR‐positive cells within CAR T cell.
TNFR1 deficiency protects against morphological alterations in the choroid plexus of APP/PS1tg/wt mice determined by TEM TNFR1 deficiency protects against.

TNFR1 deficiency protects against morphological alterations in the choroid plexus of APP/PS1tg/wt mice determined by TEM TNFR1 deficiency protects against.
App‐CTFs accumulate in the neurites and synaptic compartments in Aph1abc cKO Cre+ brains App‐CTFs accumulate in the neurites and synaptic compartments.

App‐CTFs accumulate in the neurites and synaptic compartments in Aph1abc cKO Cre+ brains App‐CTFs accumulate in the neurites and synaptic compartments.
Metabolic profile of Tfe3 KO mice

Metabolic profile of Tfe3 KO mice
Patients with Kawasaki disease but not those with mimicking conditions have significantly elevated serum and urine levels of meprin A and filamin C, which.

Patients with Kawasaki disease but not those with mimicking conditions have significantly elevated serum and urine levels of meprin A and filamin C, which.
Abnormal accumulation of U snRNPs in motor neuron nuclei of ALS patients.A–D.Immunofluorescent staining of TDP‐43 and U snRNPs using an anti‐Sm proteins.

Abnormal accumulation of U snRNPs in motor neuron nuclei of ALS patients.A–D.Immunofluorescent staining of TDP‐43 and U snRNPs using an anti‐Sm proteins.
Phenogenetic networks of genes linked to Alzheimer's and Parkinson's disease reveal concordant phenotypes Phenogenetic networks of genes linked to Alzheimer's.

Phenogenetic networks of genes linked to Alzheimer's and Parkinson's disease reveal concordant phenotypes Phenogenetic networks of genes linked to Alzheimer's.
Clinical testing of calcineurin inhibitors cyclosporine A and tacrolimus in autoimmune disorders Clinical testing of calcineurin inhibitors cyclosporine.

Clinical testing of calcineurin inhibitors cyclosporine A and tacrolimus in autoimmune disorders Clinical testing of calcineurin inhibitors cyclosporine.

Similar presentations

Ads by Google